WT1 protein-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

WT1 protein-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: ATA520; WT1 peptide-specific T-cells - Atara/MSKCC; WT1-CTL - Atara/MSKCC; WT1-sensitised T cells - Atara/MSKCC; WT1-targeted T cells - Atara/MSKCC

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Leukaemia; Multiple myeloma

Most Recent Events

  • 15 Mar 2017 Atara Biotherapeutics plans a phase I/II clinical trial in patients with Hematologic malignancies in 2018 (Atara Biotherapeutics Form 10-K, December 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Leukaemia in USA (IV, Infusion)
  • 08 Dec 2015 Efficacy and adverse events data from a phase I trial in Multiple myeloma presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2015) .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top